La Jolla Pharmaceutical Company (NASDAQ: LJPC)

La Jolla Pharmaceutical Company (NASDAQ: LJPC) is focused on improving and preserving human life through the development of novel pharmaceutical products. Riquent®, the company’s leading product in development, treats lupus renal disease, a leading cause of sickness and death in patients with lupus, by preventing or delaying renal flares. Additionally, La Jolla has developed small molecules designed to treat other autoimmune and inflammatory conditions. For further information, visit the Company’s web site at www.ljpc.com.